Compare
Viskase Holdings, Inc. vs Ocugen, Inc. vs PharmaCyte Biotech, Inc. vs Cognition Therapeutics Inc
| Latest fiscal year | Viskase Holdings, Inc. VISKRevenue covers only part of its income (partial revenue) | Ocugen, Inc. OCGN | PharmaCyte Biotech, Inc. PMCB | Cognition Therapeutics Inc CGTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-04-30 | 2025-12-31 |
| Revenue | n/a | $4.41M | $0 | n/a |
| Revenue growth (YoY) | n/a | +8.8% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$3.41M | -$67.85M | -$19.42M | -$23.49M |
| EPS (Diluted) | -$0.07 | n/a | -$2.77 | -$0.32 |
| Operating cash flow | -$3.01M | -$56.96M | -$5.15M | -$24.59M |
| Free cash flow | n/a | -$57.15M | n/a | n/a |
| Cash & equivalents | $42.57M | n/a | $18.60M | $36.81M |
| Total assets | $42.81M | $43.52M | $46.75M | $48.39M |
| Total liabilities | n/a | $55.68M | $11.77M | $14.12M |
| Shareholders' equity | -$2.52M | -$12.17M | $33.29M | $34.27M |
| Return on year-end equity | n/a | n/a | -58.3% | -68.5% |
| Shares outstanding | 74.21M | 312.38M | 10.74M | 88.90M |
Revenue, most recent five fiscal years
| Fiscal year | Viskase Holdings, Inc. | Ocugen, Inc. | PharmaCyte Biotech, Inc. | Cognition Therapeutics Inc |
|---|---|---|---|---|
| Latest | n/a | $4.41M Ended 2025-12-31 | $0 Ended 2026-04-30 | n/a |
| 1 year earlier | n/a | $4.05M Ended 2024-12-31 | $0 Ended 2025-04-30 | n/a |
| 2 years earlier | n/a | $6.04M Ended 2023-12-31 | $0 Ended 2024-04-30 | n/a |
| 3 years earlier | n/a | $2.49M Ended 2022-12-31 | $0 Ended 2023-04-30 | n/a |
| 4 years earlier | n/a | n/a | $0 Ended 2022-04-30 | n/a |